Fosun Pharma said to mull sale of USD 3.6 billion Gland Pharma
Fosun Pharma acquired a 74 percent stake in Gland for about $1.1 billion in 2017 from an investor group including KKR & Co.
Advertisement
Shanghai: Billionaire Guo Guangchang's Shanghai Fosun Pharmaceutical Group Co. is considering a sale of Indian drugmaker Gland Pharma Ltd. after receiving interest from potential buyers, people familiar with the matter said.
Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said. Companies in the industry and buyout firms are in the early stages of studying the business, the people said, asking not to be identified because the matter is private.
Shares of Gland jumped as much as 5.7 percent in Mumbai following the Bloomberg News report, their largest intraday increase in almost a month. They have fallen about 53 percent this year, giving the company a market value of $3.6 billion. Fosun Pharma shares in Hong Kong rose as much as 5.4 percent.
Hyderabad-based Gland specializes in injectable drugs such as antibiotics, oncology, and cardiology treatments and has a presence in about 60 countries, according to its website.
A sale would help Gland's Chinese owner raise cash as the once-acquisitive group seeks to shore up its balance sheet. Fosun International has been exploring options for a number of assets, including French resort operator Club Med and some domestic food and beverage operations, Bloomberg News has reported.
Fosun Pharma's high valuation expectations could present a hurdle to any potential deal amid a tough financing environment, the people said. It hasn't kicked off a formal sale process, and there's no certainty the deliberations will lead to a transaction, the people said.
Representatives for Fosun Pharma didn't immediately respond to requests for comment, while a spokesperson for Gland declined to comment.
Fosun Pharma acquired a 74 percent stake in Gland for about $1.1 billion in 2017 from an investor group including KKR & Co. It listed the business three years later in an $873 million initial public offering in Mumbai, according to data compiled by Bloomberg.
Read also: Gland Pharma eyeing complex injectables, biosimilar space to fuel future growth
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.